Titre :

Safety of 6'-sialyllactose (6'-SL) sodium salt produced by derivative strains of <i>Escherichia coli</i> BL21 (DE3) as a novel food pursuant to Regulation (EU) 2015/2283.

Auteur(s) :

Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bohn, Torsten [Auteur]
Castenmiller, Jacqueline [Auteur]
De Henauw, Stefaan [Auteur]
Hirsch-Ernst, Karen I. [Auteur]
Maciuk, Alexandre [Auteur]
Mangelsdorf, Inge [Auteur]
Mcardle, Harry J. [Auteur]
Naska, Androniki [Auteur]
Pelaez, Carmen [Auteur]
Pentieva, Kristina [Auteur]
Siani, Alfonso [Auteur]
Thies, Frank [Auteur]
Tsabouri, Sophia [Auteur]
Vinceti, Marco [Auteur]
Cubadda, Francesco [Auteur]
Frenzel, Thomas [Auteur]
Heinonen, Marina [Auteur]
Marchelli, Rosangela [Auteur]
Neuhäuser-Berthold, Monika [Auteur]
Poulsen, Morten [Auteur]
Maradona, Miguel Prieto [Auteur]
Schlatter, Josef R. [Auteur]
Van Loveren, Henk [Auteur]
Colombo, Paolo [Auteur]
Noriega Fernández, Estefanía [Auteur]
Knutsen, Helle K. [Auteur]

Titre de la revue :

EFSA Journal

Nom court de la revue :

EFSA J

Numéro :

20

Pagination :

e07645

Date de publication :

2022-12-15

ISSN :

1831-4732

Mot(s)-clé(s) en anglais :

6'-sialyllactose
6'-SL sodium salt
human milk oligosaccharide
HMO
HiMO
novel food
safety

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6′-sialyllactose (6’-SL) sodium salt as a novel food (NF) pursuant to ...
Lire la suite >Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6′-sialyllactose (6’-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 6’-SL, but it also contains d-lactose, 6′-sialyllactulose, sialic acid, N-acetyl-d-glucosamine and a small fraction of other related oligosaccharides. The NF is produced by fermentation with two genetically modified strains of Escherichia coli BL21 (DE3), the production strain and the optional degradation strain. The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements. The target population is the general population. In some scenarios at the maximum use levels, the estimated intakes per kg body weight were higher than the high average natural intake of 6’-SL from human milk. However, given the intrinsic nature of human milk oligosaccharides (HMOs), the wide range of intakes from human milk, and considering that infants are naturally exposed to similar amounts of these substances, the Panel considers that the consumption of the NF at the proposed conditions of use does not raise safety concerns. The intake of 6’-SL in breastfed infants on a body weight basis is also expected to be safe for other population groups. The intake of other carbohydrate-type compounds structurally related to 6’-SL is also considered of no safety concern. Food supplements are not intended to be used if other foods with added 6’-SL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T23:54:20Z
2024-01-30T09:15:54Z